PYXIS ONCOLOGY, INC. logo

PYXS

PYXIS ONCOLOGY, INC.

$1.39

Earnings Summary

Revenue
$0Mn
Net Profits
$-25.56Mn
Net Profit Margins
-Inf%

Highlights

Revenue:

PYXIS ONCOLOGY, INC.’s revenue jumped NaN% since last year same period to $0Mn in the Q2 2022. On a quarterly growth basis, PYXIS ONCOLOGY, INC. has generated NaN% jump in its revenue since last 3-months.

Net Profits:

PYXIS ONCOLOGY, INC.’s net profit fell -213.8% since last year same period to $-25.56Mn in the Q2 2022. On a quarterly growth basis, PYXIS ONCOLOGY, INC. has generated 18.54% jump in its net profits since last 3-months.

Net Profit Margins:

PYXIS ONCOLOGY, INC.’s net profit margin jumped NaN% since last year same period to -Inf% in the Q2 2022. On a quarterly growth basis, PYXIS ONCOLOGY, INC. has generated NaN% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the PYXIS ONCOLOGY, INC. post its latest quarter earnings

EPS Estimate Current Quarter
-0.85
EPS Estimate Current Year
-0.85

Highlights

EPS Estimate Current Quarter:

PYXIS ONCOLOGY, INC.’s earning per share (EPS) estimates for the current quarter stand at -0.85 - a -6.89% fall from last quarter’s estimates.

EPS Estimate Current Year:

PYXIS ONCOLOGY, INC.’s earning per share (EPS) estimates for the current year stand at -0.85.

Key Ratios

Key ratios of the PYXIS ONCOLOGY, INC. post its Q4 2022 earnings

Earning Per Share (EPS)
0

Highlights

Earning Per Share (EPS):

PYXIS ONCOLOGY, INC.’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q4 2022. This indicates that the PYXIS ONCOLOGY, INC. has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-03-29
-0.36
-0.53
-44.31%
2021-11-15
-0.53
-8.96
-1605.69%

Company Information

Pyxis Oncology, Inc. is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. Pyxis develops its product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Since its launch in 2019, Pyxis has developed a broad portfolio of novel antibody drug conjugate, or ADC, product candidates, and monoclonal antibody, or mAb, preclinical discovery programs that it is developing as monotherapies and in combination with other therapies.

Organisation
PYXIS ONCOLOGY, INC.
Headquarters
35 Cambridgepark Drive, Cambridge, MA, United States, 02140
Employees
73
Industry
Healthcare

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*